The first patients have been injected in a Phase 3 trial investigating the safety and performance of Blue Earth Diagnostics‘ imaging agent rhPSMA-7.3 (18F) in detecting prostate cancer in men with suspected disease recurrence, the company announced. The SPOTLIGHT trial (NCT04186845) is recruiting patients at several sites in the U.S. and at a single site in Finland. It aims to enroll about 300 men in whom prostate cancer is thought to have returned based on elevated prostate-specific antigen…
You must be logged in to read/download the full post.
The post Dosing Begins in Trial of PET Imaging Agent to Detect Prostate Cancer’s Return appeared first on BioNewsFeeds.